EcoDrugPlus

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSAMXG00000000426
Gene Symbol: PSMA3
3 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSAMXG00000013834
Gene Symbol: PSMA4
3 Cross references
199 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSAMXG00000006729
Gene Symbol: PSMA5
3 Cross references
212 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSAMXG00000039104
Gene Symbol: PSMA6
3 Cross references
229 Possible Orthologues:

Proteasome 20s Subunit Alpha 7

Ensembl ID : ENSAMXG00000041229
Gene Symbol: PSMA7
2 Cross references
158 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSAMXG00000033075
Gene Symbol: PSMB1
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 11b

Ensembl ID : ENSAMXG00000041727
Gene Symbol: PSMB11B
1 Cross references
161 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSAMXG00000010339
Gene Symbol: PSMB2
3 Cross references
222 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSAMXG00000043971
Gene Symbol: PSMB3
3 Cross references
261 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSAMXG00000020525
Gene Symbol: PSMB4
3 Cross references
215 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSAMXG00000033908
Gene Symbol: PSMB5
3 Cross references
223 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSAMXG00000002691
Gene Symbol: PSMB6
1 Cross references
232 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).